Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Taiwan ODM expert factory for comfort product development

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Insole ODM factory in Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Cushion insole OEM solution Taiwan

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Orthopedic pillow OEM solutions Vietnam

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Taiwan flexible graphene product manufacturing factory

Rhynchocalamus hejazicus pictured in life. Credit: Fulvio Licata Researchers have identified a new snake species in the Hejaz region of Saudi Arabia. Named Rhynchocalamus hejazicus, this small snake is notable for its black collar and reddish coloration, which sets it apart from its closest relatives. Additionally, a uniformly black variant of the species, known as the ‘melanistic morphotype,’ has been discovered. Rhynchocalamus hejazicus is prevalent throughout a large area, bridging the distribution gap between the Levant and the coastal regions of Yemen and Oman for the Rhynchocalamus genus. The species was discovered by an international team of scientists from the Centro de Investigação em Biodiversidade e Recursos Genéticos (CIBIO) in Portugal and Charles University in the Czech Republic. Their findings were published in Zoosystematics and Evolution, a journal published by Pensoft on behalf of Museum für Naturkunde Berlin. Black ‘melanistic morphotype’ of Rhynchocalamus hejazicus pictured in life. Credit: Fulvio Licata Habitat and Conservation Status Rhynchocalamus hejazicus inhabits sandy and stony soils with varying vegetation cover and can be found in habitats disturbed by humans. This adaptability suggests that the species is not currently at risk of extinction, according to IUCN criteria. Little is known about the species’ natural history and behavior. Further monitoring and conservation efforts are necessary to better understand its ecological dynamics. However, it appears that Rhynchocalamus hejazicus is predominantly nocturnal, as all observed individuals were encountered at night. Habitats of Rhynchocalamus hejazicus: Top: Shaaran NR, AlUla County, Medina Province, KSA; bottom left: Wadi Al-Azraq, Jabal Salma, Hail Province, KSA; bottom right: Harrat Khaybar, Hail Province, KSA. Credit: Fulvio Licata and Adel A. Ibrahim Significance of the Discovery “The discovery of a new species of snake widespread in the central-western regions of Saudi Arabia is surprising and gives rise to the hope that more undiscovered species might be present in the Kingdom” the authors say. Most of the observations of the new species result from intense sampling efforts in a vast area around the ancient Arabic oasis city of AlUla. These efforts are fostered by the Royal Commission for AlUla, Saudi Arabia, which is advancing scientific activities and explorations to promote conservation in the region. The intensification of field studies in Saudi Arabia in recent years has led to fruitful collaborations and significant findings like this study, to which many experts from multiple teams have contributed. Rhynchocalamus hejazicus pictured in life. Credit: Fulvio Licata The discovery of such a distinctive snake underscores the existing gap in the description of rare and secretive species and highlights the need to enhance sampling efforts and monitoring strategies to fully capture species diversity in unexplored areas. Reference: “The missing piece of the puzzle: A new and widespread species of the genus Rhynchocalamus Günther, 1864 (Squamata, Colubridae) from the Arabian Peninsula” by Fulvio Licata, Lukáš Pola, Jiří Šmíd, Adel A. Ibrahim, André Vicente Liz, Bárbara Santos, László Patkó, Ayman Abdulkareem, Duarte V. Gonçalves, Ahmed Mohajja AlShammari, Salem Busais, Damien M. Egan, Ricardo M. O. Ramalho, Josh Smithson, and José Carlos Brito, 30 May 2024, Zoosystematics and Evolution. DOI: 10.3897/zse.100.123441

Ketamine is a powerful anesthetic drug that is used in medicine for surgical procedures and pain management. It is also used as a recreational drug for its mind-altering and hallucinogenic effects. In recent years, ketamine has gained attention for its potential as a rapid-acting treatment for depression, anxiety, and other mental health disorders. However, its use for depression is still considered off-label and more research is needed to fully understand its effects and safety. A study has identified a potential mechanism behind the delusions and hallucinations experienced by individuals with schizophrenia. An international team of researchers, including Sofya Kulikova, a Senior Research Fellow at HSE University-Perm, discovered that ketamine’s role as an NMDA receptor inhibitor amplifies the brain’s background noise, resulting in higher entropy of incoming sensory signals and disrupts the transmission between the thalamus and cortex. These findings may contribute to a deeper understanding of the origin of psychosis in schizophrenia. The research has recently been published in the European Journal of Neuroscience. Schizophrenia-related disorders impact around 1 in 300 people globally. The most widespread symptoms of these conditions are perceptual disturbances such as hallucinations, delusions, and psychoses. NMDA Receptors and Sensory Signal Processing A drug called ketamine can induce a mental state similar to psychosis in healthy individuals. Ketamine inhibits NMDA receptors involved in the transmission of excitatory signals in the brain. An imbalance of excitation and inhibition in the central nervous system can affect the accuracy of sensory perception. Pre-stimulus beta and gamma frequencies on cortical and thalamic recordings are significantly higher under ketamine conditions (right) compared to saline (left) conditions. Credit: Yi Qin et all. European Journal of Neuroscience Similar changes in the functioning of NMDA receptors are currently believed to be one of the causes of perception disorders in schizophrenia. However, it is still unclear how exactly this process occurs in the brain regions involved. The Thalamocortical System and Sensory Oscillations To find out, neuroscientists from France, Austria, and Russia studied how the brains of laboratory rats on ketamine process sensory signals. The researchers examined beta and gamma oscillations occurring in response to sensory stimuli in the rodent brain’s thalamocortical system, a neural network connecting the cerebral cortex with the thalamus responsible for the transmission of sensory information from the organs of perception to the brain. Beta oscillations are brainwaves in the range of 15 to 30 Hz, and gamma waves are those in the range of 30 to 80 Hz. These frequencies are believed to be critical for encoding and integrating sensory information. In the experiment, rats were implanted with microelectrodes to record the electrical activity in the thalamus and the somatosensory cortex, a region of the brain that is responsible for processing sensory information coming from the thalamus. The researchers stimulated the rats’ whiskers (vibrissae) and recorded the brain’s responses before and after ketamine administration. A comparison of the two datasets revealed that ketamine increased the power of beta and gamma oscillations in the cortex and the thalamus even in the resting state before a stimulus was presented, while the amplitude of the beta/gamma oscillations in the 200–700 ms post-stimulus period was significantly lower at all recorded cortical and thalamic sites following ketamine administration. The post-stimulation time lapse of 200–700 ms is long enough to encode, integrate and perceive the incoming sensory signal. The observed decrease in the power of sensory stimulus-induced oscillations can be associated with impaired perception. Noise Interference and Impaired Perception Analysis also revealed that by inhibiting NMDA receptors, ketamine administration added noise to gamma frequencies in the post-stimulation 200–700 ms period in one thalamic nucleus and in one layer of the somatosensory cortex. It can be assumed that this observed increase in noise, ie a reduction in the signal-to-noise ratio, also indicates the neurons’ impaired ability to process incoming sensory signals. These findings suggest that psychosis may be triggered by an increase in background noise impairing the function of thalamocortical neurons. This, in turn, could be caused by a malfunction of NMDA receptors affecting the balance of inhibition and excitation in the brain. The noise makes sensory signals less defined or pronounced. In addition, this may cause spontaneous outbursts of activity associated with a distorted perception of reality. “The discovered alterations in thalamic and cortical electrical activity associated with ketamine-induced sensory information processing disorders could serve as biomarkers for testing antipsychotic drugs or predicting the course of disease in patients with psychotic spectrum disorders,” states Sofya Kulikova Ph.D., Senior Research Fellow at the HSE University-Perm. Reference: “The psychotomimetic ketamine disrupts the transfer of late sensory information in the corticothalamic network” by Yi Qin, Ali Mahdavi, Marine Bertschy, Paul M. Anderson, Sofya Kulikova and Didier Pinault, 13 October 2022, European Journal of Neuroscience. DOI: 10.1111/ejn.15845

Researchers have identified a biomarker in brain activity reflecting recovery in patients with treatment-resistant depression using deep brain stimulation (DBS) and AI, promising more personalized treatment approaches. Harnessing the power of explainable AI, researchers have unveiled the first insights into the complex workings of deep-brain stimulation therapy for treatment-resistant depression. A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression. This pattern, known as a biomarker, serves as a measurable indicator of disease recovery and represents a significant advance in treatment for the most severe and untreatable forms of depression. The Significance of DBS The team’s findings, published online in the journal Nature on September 20, offer the first window into the intricate workings and mechanistic effects of DBS on the brain during treatment for severe depression. DBS involves implanting thin electrodes in a specific brain area to deliver small electrical pulses, similar to a pacemaker. Although DBS has been approved and used for movement disorders such as Parkinson’s disease for many years, it remains experimental for depression. This study is a crucial step toward using objective data collected directly from the brain via the DBS device to inform clinicians about the patient’s response to treatment. This information can help guide adjustments to DBS therapy, tailoring it to each patient’s unique response and optimizing their treatment outcomes. Monitoring and Tools for Treatment Now, the researchers have shown it’s possible to monitor that antidepressant effect throughout the course of treatment, offering clinicians a tool somewhat analogous to a blood glucose test for diabetes or blood pressure monitoring for heart disease: a readout of the disease state at any given time. Importantly, it distinguishes between typical day-to-day mood fluctuations and the possibility of an impending relapse of the depressive episode. The research team, which includes experts from the Georgia Institute of Technology, the Icahn School of Medicine at Mount Sinai, and Emory University School of Medicine, used artificial intelligence (AI) to detect shifts in brain activity that coincided with patients’ recovery. The Study and Its Findings The study, funded by the National Institutes of Health Brain Research Through Advancing Innovative Neurotechnologies ®, or the BRAIN Initiative ®, involved 10 patients with severe treatment-resistant depression, all of whom underwent the DBS procedure at Emory University. The study team used a new DBS device that allowed brain activity to be recorded. Analysis of these brain recordings over six months led to the identification of a common biomarker that changed as each patient recovered from their depression. After six months of DBS therapy, 90 percent of the subjects exhibited a significant improvement in their depression symptoms and 70 percent no longer met the criteria for depression. The high response rates in this study cohort enabled the researchers to develop algorithms known as “explainable artificial intelligence” that allow humans to understand the decision-making process of AI systems. This technique helped the team identify and understand the unique brain patterns that differentiated a “depressed” brain from a “recovered” brain. Expert Insights “The use of explainable AI allowed us to identify complex and usable patterns of brain activity that correspond to a depression recovery despite the complex differences in a patient’s recovery,” explained Sankar Alagapan PhD, a Georgia Tech research scientist and lead author of the study. ”This approach enabled us to track the brain’s recovery in a way that was interpretable by the clinical team, making a major advance in the potential for these methods to pioneer new therapies in psychiatry.” Helen S. Mayberg, MD, co-senior author of the study, led the first experimental trial of subcallosal cingulate cortex (SCC) DBS for treatment-resistant depression patients in 2003, demonstrating that it could have clinical benefit. In 2019, she and the Emory team reported the technique had a sustained and robust antidepressant effect with ongoing treatment over many years for previously treatment-resistant patients. “This study adds an important new layer to our previous work, providing measurable changes underlying the predictable and sustained antidepressant response seen when patients with treatment-resistant depression are precisely implanted in the SCC region and receive chronic DBS therapy,” said Dr. Mayberg, now Founding Director of the Nash Family Center for Advanced Circuit Therapeutics at Icahn Mount Sinai. “Beyond giving us a neural signal that the treatment has been effective, it appears that this signal can also provide an early warning signal that the patient may require a DBS adjustment in advance of clinical symptoms. This is a game changer for how we might adjust DBS in the future.“ Multi-Disciplinary Collaboration “Understanding and treating disorders of the brain are some of our most pressing grand challenges, but the complexity of the problem means it’s beyond the scope of any one discipline to solve,” said Christopher Rozell, PhD, Julian T. Hightower Chair and Professor of Electrical and Computer Engineering at Georgia Tech and co-senior author of the paper. “This research demonstrates the immense power of interdisciplinary collaboration. By bringing together expertise in engineering, neuroscience, and clinical care, we achieved a significant advance toward translating this much-needed therapy into practice, as well as an increased fundamental understanding that can help guide the development of future therapies.” The team’s research also confirmed a longstanding subjective observation by psychiatrists: as patients’ brains change and their depression eases, their facial expressions also change. The team’s AI tools identified patterns in individual facial expressions that corresponded with the transition from a state of illness to stable recovery. These patterns proved more reliable than current clinical rating scales. In addition, the team used two types of magnetic resonance imaging to identify both structural and functional abnormalities in the brain’s white matter and interconnected regions that form the network targeted by the treatment. They found these irregularities correlate with the time required for patients to recover, with more pronounced deficits in the targeted brain network correlated to a longer time for the treatment to show maximum effectiveness. These observed facial changes and structural deficits provide behavioral and anatomical evidence supporting the relevance of the electrical activity signature or biomarker. Moving Forward “When we treat patients with depression, we rely on their reports, a clinical interview, and psychiatric rating scales to monitor symptoms. Direct biological signals from our patients’ brains will provide a new level of precision and evidence to guide our treatment decisions,” said Patricio Riva-Posse, MD, Associate Professor and Director of the Interventional Psychiatry Service in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, and lead psychiatrist for the study. Given these initial promising results, the team is now confirming their findings in another completed cohort of patients at Mount Sinai. They are using the next generation of the dual stimulation/sensing DBS system with the aim of translating these findings into the use of a commercially available version of this technology. Reference: “Cingulate dynamics track depression recovery with deep brain stimulation” by Sankaraleengam Alagapan, Ki Sueng Choi, Stephen Heisig, Patricio Riva-Posse, Andrea Crowell, Vineet Tiruvadi, Mosadoluwa Obatusin, Ashan Veerakumar, Allison C. Waters, Robert E. Gross, Sinead Quinn, Lydia Denison, Matthew O’Shaughnessy, Marissa Connor, Gregory Canal, Jungho Cha, Rachel Hershenberg, Tanya Nauvel, Faical Isbaine, Muhammad Furqan Afzal, Martijn Figee, Brian H. Kopell, Robert Butera, Helen S. Mayberg and Christopher J. Rozell, 20 September 2023, Nature. DOI: 10.1038/s41586-023-06541-3 Research reported in this press release was supported by the National Institutes of Health BRAIN Initiative under award number UH3NS103550; the National Science Foundation, grant No. CCF-1350954; the Hope for Depression Research Foundation; and the Julian T. Hightower Chair at Georgia Tech. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of any funding agency.

DVDV1551RTWW78V